# SIYATA MOBILE INC.

Consolidated Unaudited Interim Financial Statements (Expressed in US Dollars)

As at March 31, 2023 and December 31, 2022 and for the three months ended March 31, 2023 and 2022

# NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The Management of the Company is responsible for the preparation of the accompanying unaudited condensed interim consolidated financial statements. The unaudited condensed interim consolidated financial statements have been prepared using accounting policies in compliance with International Financial Reporting Standards ("IFRS") for the preparation of consolidated interim financial statements and are in accordance with International Accounting Standards ("IAS") 34 – Interim Financial Reporting.

The Company's independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

# Siyata Mobile Inc. Unaudited Condensed Interim Consolidated Statements of Financial Position (Expressed in US dollars)

		March 31, 2023	December 31, 2022
ASSETS			
Current			
Cash		\$ 1,179,694	\$ 1,913,742
Trade and other receivables (Note 3)		1,111,123	1,574,628
Prepaid expenses		665,446	173,504
Inventory (Note 4)		3,564,040	4,092,550
Advance to suppliers		675,561	155,852
		7,195,864	7,910,276
Long term receivable		146,196	150,185
Right of use assets		811,966	887,137
Equipment		199,743	207,402
Intangible assets		7,481,391	6,987,531
Total assets		\$ 15,835,160	
i otal assets		÷ 13,053,100	φ 10,142,551
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current			
Accounts payable and accrued liabilities		\$ 2,111,174	
Deferred revenue		-	149,600
Lease obligations		294,359	303,788
Warrant liability (Note 6)		628,765	2,734,804
		3,034,298	6,266,842
Lease obligations		543,944	635,217
Total liabilities		3,578,242	6,902,059
			0,902,009
Shareholders' equity			<b>53 313</b> 044
Share capital (Note 7)		79,626,690	73,312,866
Reserves (Note 7)		17,933,273	13,647,399
Accumulated other comprehensive loss		98,870	98,870
Deficit		(85,401,915)	
		12,256,918	9,240,472
Total liabilities and shareholders' equity		<u>\$ 15,835,160</u>	\$ 16,142,531
Nature of operations and going concern (Note 1) Subsequent events (Note 16)			
Approved on May 24, 2023 on behalf of the Board: <i>"Michael Kron"</i>	"Marc Seelenfreund"		

Michael Kron - Director

Marc Seelenfreund - Director

# Siyata Mobile Inc. Unaudited Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Expressed in US dollars) For the three months ended March 31

	2023	2022
D	¢ 1 902 (27	¢ 922.074
Revenue	\$ 1,802,637	
Cost of sales (Note 8)	(1,306,120)	(577,923)
Gross profit	496,517	255,051
EXPENSES		
Amortization and depreciation	401,640	124,505
Development expenses	53,985	123,316
Selling and marketing (Note 9)	1,003,365	1,045,051
General and administrative (Note 10)	1,392,430	1,659,079
Inventory impairment (Note 4)	-	64,336
Bad debts (recovered) (Note 3)	-	(7,358)
Share-based payments (Note 7)	310,828	812,735
Total operating expenses	3,162,248	3,821,664
Net operating loss	(2,665,731)	(3,566,613)
OTHER EXPENSES		
Finance expense	34,098	26,987
Foreign exchange	163	(87,660)
Change in fair value of convertible promissory note (Note 5)	-	2,680,457
Change in fair value of warrant liability (Note 6)	4,883,260	(3,272,735)
Transaction costs (Note 11)	-	965,247
Total other expenses (income)	4,917,521	312,296
Net loss for the year	(7,583,252)	(3,878,909)
Other comprehensive income		
Translation adjustment	-	(24,468)
Comprehensive loss for the year	\$(7,583,252)	\$(3,903,377)
Weighted average shares	59,102,369	12,976,363
Basic and diluted loss per share	\$ (0.13)	

# Siyata Mobile Inc. Unaudited Condensed Interim Consolidated Statement of Changes in Shareholders' Equity (Expressed in US dollars) For the three months ending March 31

	Share capital #	Share Capital \$	Capital Reserves income (loss) Deficit			
Balance, December 31,	5 276 605	54 (55 344	10 200 555	(29.720)	((2 510 412)	2 496 649
2021	5,276,695	54,655,244	10,389,555	(38,/39)	(62,519,412)	2,486,648
Shares issued on acquisition	100.050	100.005				100.005
of ClearRF	138,958	190,095	-	-	-	190,095
Shares issued on capital raise	7,215,652	10,936,974	-	-	-	10,936,974
Share issuance costs on capital raise		(1,051,647)	307,189	-	-	(744,458)
Pre-funded warrants						
exercised	1,480,000	2,575,200	-	-	-	2,575,200
Share based payments	-	-	812,735		812,735	
Translation adjustment	-	-	-	24,468	-	24,468
Net loss					(3,878,909)	(3,878,909)
Balance, March 31, 2022	14,111,305	67,305,866	11,509,479	(14,271)	(66,398,321)	12,402,753
Balance, December 31,						
2022	44,868,560	73,312,866	13,647,399	98,870	(77,818,663)	9,240,472
Issue of common shares for					· · · · · · · · · · · · · · · · · · ·	
warrants	18,042,857	6,313,824	-	-	-	6,313,824
Warrants reclassified from warrant liability			3,975,046			3,975,046
Share based payments	-	=	310,828	-	-	310,828
Translation adjustment	-	-	510,828	-	-	510,828
Net loss	_	_	_	-	(7,583,252)	(7,583,252)
Balance, March 31, 2023	62,911,417	79,626,690	17,933,273	98,870	(1,505,252)	12,256,918

# Siyata Mobile Inc.

Unaudited Condensed Interim Consolidated Statements of Cash Flows (Expressed in US dollars) For the three months ended March 31

2023   2022     Operating activities   \$(7,583,252) \$(3,878,909)     Met loss for the year   401,640   124,505     Amortization and depreciation   401,640   124,505     Bad debt expense (recovered)   - (7,358)     Impairment of inventory   - 64,336     Fair value changes on derivatives   4,883,260   (592,278)     Interest expense, net of repayments   - (4,651)   (1,136,712)   (3,225,654)     Net cash used in operating activities   310,828   812,735   (5,77,274)     Investing activities   - (155,014)   (739,579)   (6,707,274)     Investing activities   - (155,014)   - (155,014)   (820,347)   (894,593)     Financing activities   - (150,112)   - (2,71,59)   (739,579)     Convertible debt issued, net of repayments   - (150,114)   - (2,71,59)     Vet cash used in investing activities   - (155,014)   - (2,71,59)     Net cash used in investing activities   - (2,71,59)   - (2,71,59)     Convertible debt issued, net of repayments   - (4,000,000)   - (2,71,59)     Convertible debt issued, net of			
Net loss for the year   \$(7,583,252) \$ (3,878,909)     Items not affecting cash:   401,640   124,505     Amortization and depreciation   401,640   124,505     Bad debt expense (recovered)   - (7,358)     Impairment of inventory   - 64,336     Fair value changes on derivatives   4,883,260   (592,278)     Interest expense, net of repayments   - (4,651)   - (4,651)     Foreign exchange   11,666   -     Share based payments   310,828   812,735     Change in non-cash working capital (Note 15)   (1,136,712)   (3,225,654)     Net cash used in operating activities    -     Repayment of long-term receivable    -     Intrastitions   (817,849)   (739,579)     Equipment additions   (2,498)   -     Acquisition of ClearRF   - (155,014)   -     Net cash used in investing activities   (820,347)   (894,593)     Financing activities   - (2,7,159)   -   -     Lease payments   - (0,70,000)   -   -   -		2023	2022
Items not affecting cash:401,640124,505Mortization and depreciation401,640124,505Bad debt expense (recovered)- (7,358)Impairment of inventory- 64,336Fair value changes on derivatives4,883,260Interest expense, net of repayments- (4,651)Foreign exchange11,666Share based payments310,828812,735(1,136,712)Change in non-cash working capital (Note 15)(1,136,712)(3,225,654)(3,112,570)Net cash used in operating activities(3,112,570)Repayment of long-term receivable-Investing activities(1,15,014)Repayment of ClearRF- (155,014)Net cash used in investing activities(820,347)Equipment additions(2,498)Icase payments- (27,159)Convertible debt issued, net of repayments- (27,159)Convertible debt issued, net of repayments- (4,000,000)Proceeds on share issuance, net of share issuance costs- (6,711,184)Transaction costs- (309,000)Exercise of warrants3,608,5712,575,200- (22,680)Change in cash for the year- (734,048)Change in cash for the year- (734,048)Change in cash for the year- (151,017)Cash, beginning of year- 1,913,7421,619,742- 1,619,742			
Amortization and depreciation 401,640 124,505   Bad debt expense (recovered) - (7,358)   Impairment of inventory - 64,336   Fair value changes on derivatives 4,883,260 (592,278)   Interest expense, net of repayments - (4,651)   Foreign exchange 11,666 -   Share based payments 310,828 812,735   Change in non-cash working capital (Note 15) (1,136,712) (3,22,564)   Net cash used in operating activities (3,112,570) (6,707,274)   Investing activities (3,112,570) (6,707,274)   Investing activities (2,498) -   Repayment of long-term receivable - -   Intangible asset additions (2,498) -   Acquisition of ClearRF - (155,014) (820,347)   Net cash used in investing activities (820,347) (824,593)   Financing activities (100,702) (78,731)   Bank loan - (27,159) (2,159)   Convertible debt issued, net of repayments - (4,000,000)   Proceeds on share issuance, net of share issuance costs - 16,711,184   Tansaction cos		\$(7,583,252) \$	(3,878,909)
Bad debt expense (recovered) - (7,358)   Impairment of inventory - 64,336   Fair value changes on derivatives 4,883,260 (592,278)   Interest expense, net of repayments - (4,651) (4,651)   Foreign exchange 11,666 -   Share based payments 310,828 812,735   Change in non-cash working capital (Note 15) (1,136,712) (3,225,654)   Net cash used in operating activities (3,112,570) (6,707,274)   Investing activities (817,849) (739,579)   Equipment additions (2,498) -   Acquisition of ClearRF - (155,014)   Net cash used in investing activities (820,347) (894,593)   Financing activities - (155,014)   Lease payments (100,702) (78,731)   Bak loan - (27,159) - (4,000,000)   Proceeds on share issuance, net of share issuance costs - (16,711,184)   Transaction costs (309,000) -   Exercise of warrants 3,608,571 2,575,200   Net cash from financing activities 3,198,869 15,180,494   Effect of foreign exchange on cash <td></td> <td></td> <td></td>			
Impairment of inventory - 64,336   Fair value changes on derivatives 4,883,260 (592,278)   Interest expense, net of repayments - (4,651)   Foreign exchange 11,666 -   Share based payments 310,828 812,735   Change in non-cash working capital (Note 15) (1,136,712) (3,225,654)   Net cash used in operating activities (3,112,570) (6,707,274)   Investing activities (817,849) (739,579)   Equipment of long-term receivable - -   Intangible asset additions (2,498) -   Acquisition of ClearFF - (155,014)   Net cash used in investing activities (820,347) (894,593)   Financing activities (100,702) (78,731)   Lease payments - 16,711,184   Transaction costs - -   Convertible debt issued, net of repayments - 16,711,184   Transaction costs (309,000) - -   Exercise of warrants 3,608,571 2,575,200   Net cash from financing activities 3,198,869 15,180,494		401,640	
Fair value changes on derivatives 4,883,260 (592,278)   Interest expense, net of repayments - (4,651)   Foreign exchange 11,666 -   Share based payments 310,828 812,735   Change in non-cash working capital (Note 15) (1,136,712) (3,222,654)   Net cash used in operating activities (3,112,570) (6,707,274)   Investing activities (3,112,570) (6,707,274)   Investing activities (817,849) (739,579)   Equipment of long-term receivable - -   Intargible asset additions (2,498) -   Acquisition of ClearRF - (155,014) (820,347)   Net cash used in investing activities (820,347) (894,593)   Financing activities (100,702) (78,731)   Bank loan - (27,159) Convertible debt issued, net of repayments - (4,000,000)   Proceeds on share issuance, net of share issuance costs - 16,711,118 - 15,712,00   Transaction costs (309,000) - Exercise of warrants 3,608,571 2,575,200   Net cash from financing activities 3,198,869 15,180,494 -		-	
Interest expense, net of repayments - (4,651)   Foreign exchange 11,666 -   Share based payments 310,828 812,735   Change in non-cash working capital (Note 15) (1,136,712) (3,225,654)   Net cash used in operating activities (3,112,570) (6,707,274)   Investing activities (3,112,570) (6,707,274)   Investing activities (817,849) (739,579)   Equipment additions (2,498) -   Acquisition of ClearRF - (155,014)   Net cash used in investing activities (820,347) (894,593)   Financing activities (100,702) (78,731)   Bank loan - (2,71,59)   Convertible debt issued, net of repayments - (4,000,000)   Proceeds on share issuance, net of share issuance costs - 16,711,184   Transaction costs (309.000) - -   Exercise of warrants 3,608,571 2,575,200   Net cash from financing activities 3,198,869 15,180,494   Effect of foreign exchange on cash - 22,680   Change in cash for the year		-	
Foreign exchange 11,666 -   Share based payments 310,828 812,735   Change in non-cash working capital (Note 15) (1,136,712) (3,225,654)   Net cash used in operating activities (3,112,570) (6,707,274)   Investing activities (3,112,570) (6,707,274)   Investing activities (817,849) (739,579)   Equipment of long-term receivable - -   Intangible asset additions (817,849) (739,579)   Equipment additions (2,498) -   Acquisition of ClearRF - (155,014)   Net cash used in investing activities (820,347) (894,593)   Financing activities (100,702) (78,731)   Bank loan - (27,159)   Convertible debt issued, net of repayments - (4,000,000)   Proceeds on share issuance, net of share issuance costs - 16,711,184   Transaction costs (309,000) - Exercise of warrants   Stercise of warrants 3,608,571 2,575,200   Net cash from financing activities 3,198,869 15,180,494   Effect of foreign exchang		4,883,260	
Share based payments   310,828   812,735     Change in non-cash working capital (Note 15)   (1,136,712)   (3,225,654)     Net cash used in operating activities   (3,112,570)   (6,707,274)     Investing activities   (3,112,570)   (6,707,274)     Investing activities   (3,112,570)   (6,707,274)     Investing activities   (817,849)   (739,579)     Equipment additions   (2,498)   -     Acquisition of ClearRF   -   (155,014)     Net cash used in investing activities   (820,347)   (894,593)     Financing activities   (100,702)   (78,731)     Bank loan   -   (27,159)     Convertible debt issued, net of repayments   -   (4,000,000)     Proceeds on share issuance, net of share issuance costs   -   16,711,184     Transaction costs   (309,000)   -   Exercise of warrants     S409,000   -   Exercise of share issuance on cash   -   22,575,200     Net cash from financing activities   3,198,869   15,180,494   Effect of foreign exchange on cash   -   22,680		-	(4,651)
Change in non-cash working capital (Note 15) $(1,136,712)$ $(3,225,654)$ Net cash used in operating activities $(3,112,570)$ $(6,707,274)$ Investing activities $(3,112,570)$ $(6,707,274)$ Investing activities $(817,849)$ $(739,579)$ Equipment additions $(2,498)$ $-$ Acquisition of ClearRF $ (155,014)$ Net cash used in investing activities $(820,347)$ $(894,593)$ Financing activities $(820,347)$ $(894,593)$ Lease payments $(100,702)$ $(78,731)$ Bank loan $ (27,159)$ Convertible debt issued, net of repayments $ (4,000,000)$ Proceeds on share issuance, net of share issuance costs $ 16,711,184$ Transaction costs $ 3,608,571$ $2,575,200$ Net cash from financing activities $ 22,680$ Change in cash for the year $(734,048)$ $7,601,307$ Cash, beginning of year $1,913,742$ $1,619,742$		· · · · · · · · · · · · · · · · · · ·	-
Net cash used in operating activities(3,112,570)(6,707,274)Investing activitiesRepayment of long-term receivableIntangible asset additions(817,849)Equipment additions(2,498)Acquisition of ClearRFNet cash used in investing activitiesFinancing activitiesLease paymentsLease paymentsConvertible debt issued, net of repayments(4,000,000)Proceeds on share issuance, net of share issuance costsTransaction costs(309.000)Exercise of warrants3,608,5712,575,200Net cash from financing activitiesEffect of foreign exchange on cash-22,680Change in cash for the yearChange in cash for			
Investing activitiesRepayment of long-term receivableIntangible asset additions(817,849)Equipment additionsAcquisition of ClearRFAcquisition of ClearRF(820,347)RepaymentsLease paymentsLease payments(100,702)Convertible debt issued, net of repayments(4,000,000)Proceeds on share issuance, net of share issuance costs16,711,184Transaction costsExercise of warrants3,608,5712,575,200Net cash from financing activitiesEffect of foreign exchange on cash-22,680Change in cash for the yearChange in cash for the yearChange in cash for the year19,13,7421,619,742	Change in non-cash working capital (Note 15)	(1,136,712)	(3,225,654)
Repayment of long-term receivable-Intangible asset additions(817,849)Equipment additions(2,498)Acquisition of ClearRF-Net cash used in investing activities(820,347)Equation activities(820,347)Lease payments(100,702)Convertible debt issued, net of repayments-Proceeds on share issuance, net of share issuance costs-100,701(78,731)Convertible debt issued, net of repayments-100,702(78,731)Proceeds on share issuance, net of share issuance costs-16,711,184-Transaction costs-Exercise of warrants3,608,5712,575,200-Net cash from financing activities-22,680-Change in cash for the year(734,048)7,601,307-Cash, beginning of year1,913,7421,619,742	Net cash used in operating activities	(3,112,570)	(6,707,274)
Repayment of long-term receivable-Intangible asset additions(817,849)Equipment additions(2,498)Acquisition of ClearRF-Net cash used in investing activities(820,347)Equation activities(820,347)Lease payments(100,702)Convertible debt issued, net of repayments-Proceeds on share issuance, net of share issuance costs-100,701(78,731)Convertible debt issued, net of repayments-100,702(78,731)Proceeds on share issuance, net of share issuance costs-16,711,184-Transaction costs-Exercise of warrants3,608,5712,575,200-Net cash from financing activities-22,680-Change in cash for the year(734,048)7,601,307-Cash, beginning of year1,913,7421,619,742			
Repayment of long-term receivable-Intangible asset additions(817,849)Equipment additions(2,498)Acquisition of ClearRF-Net cash used in investing activities(820,347)Equation activities(820,347)Lease payments(100,702)Convertible debt issued, net of repayments-Proceeds on share issuance, net of share issuance costs-100,701(78,731)Convertible debt issued, net of repayments-100,702(78,731)Proceeds on share issuance, net of share issuance costs-16,711,184-Transaction costs-Exercise of warrants3,608,5712,575,200-Net cash from financing activities-22,680-Change in cash for the year(734,048)7,601,307-Cash, beginning of year1,913,7421,619,742	Investing activities		
Intangible asset additions(817,849)(739,579)Equipment additions(2,498)-Acquisition of ClearRF-(155,014)Net cash used in investing activities(820,347)(894,593)Financing activities(100,702)(78,731)Bank loan-(27,159)Convertible debt issued, net of repayments-(4,000,000)Proceeds on share issuance, net of share issuance costs-16,711,184Transaction costs(309,000)-Exercise of warrants3,608,5712,575,200Net cash from financing activities-22,680Change in cash for the year(734,048)7,601,307Cash, beginning of year1,913,7421,619,742		-	-
Equipment additions(2,498)Acquisition of ClearRF-Net cash used in investing activities(820,347)Financing activities(820,347)Lease payments(100,702)Lease payments-Convertible debt issued, net of repayments-Proceeds on share issuance, net of share issuance costs-16,711,184Transaction costs-Exercise of warrants3,608,5712,575,200Net cash from financing activities-22,680Change in cash for the year(734,048)7,601,307Cash, beginning of year1,913,7421,619,742		(817,849)	(739,579)
Acquisition of ClearRF- (155,014)Net cash used in investing activities(820,347)Lease payments(100,702)Lease payments- (27,159)Convertible debt issued, net of repayments- (4,000,000)Proceeds on share issuance, net of share issuance costs- 16,711,184Transaction costs- 3,608,571Exercise of warrants- 3,608,571Strength activities- 22,680Change in cash for the year(734,048)Change in cash for the year- 16,9742			-
Net cash used in investing activities   (820,347)   (894,593)     Financing activities   [100,702)   (78,731)     Lease payments   (100,702)   (78,731)     Bank loan   - (27,159)   (4,000,000)     Proceeds on share issuance, net of repayments   - (4,000,000)     Proceeds on share issuance, net of share issuance costs   - 16,711,184     Transaction costs   (309,000)   -     Exercise of warrants   3,608,571   2,575,200     Net cash from financing activities   3,198,869   15,180,494     Effect of foreign exchange on cash   - 22,680   -     Change in cash for the year   (734,048)   7,601,307     Cash, beginning of year   1,913,742   1,619,742		-	(155,014)
Financing activities   Lease payments (100,702) (78,731)   Bank loan - (27,159)   Convertible debt issued, net of repayments - (4,000,000)   Proceeds on share issuance, net of share issuance costs - 16,711,184   Transaction costs (309,000) -   Exercise of warrants 3,608,571 2,575,200   Net cash from financing activities 3,198,869 15,180,494   Effect of foreign exchange on cash - 22,680   Change in cash for the year (734,048) 7,601,307   Cash, beginning of year 1,913,742 1,619,742		(820.347)	
Lease payments (100,702) (78,731)   Bank loan - (27,159)   Convertible debt issued, net of repayments - (4,000,000)   Proceeds on share issuance, net of share issuance costs - 16,711,184   Transaction costs (309.000) -   Exercise of warrants 3,608,571 2,575,200   Net cash from financing activities 3,198,869 15,180,494   Effect of foreign exchange on cash - 22,680   Change in cash for the year (734,048) 7,601,307   Cash, beginning of year 1,913,742 1,619,742		(020,011)	(0) 1,000)
Lease payments (100,702) (78,731)   Bank loan - (27,159)   Convertible debt issued, net of repayments - (4,000,000)   Proceeds on share issuance, net of share issuance costs - 16,711,184   Transaction costs (309.000) -   Exercise of warrants 3,608,571 2,575,200   Net cash from financing activities 3,198,869 15,180,494   Effect of foreign exchange on cash - 22,680   Change in cash for the year (734,048) 7,601,307   Cash, beginning of year 1,913,742 1,619,742	Financing activities		
Bank loan- (27,159)Convertible debt issued, net of repayments- (4,000,000)Proceeds on share issuance, net of share issuance costs- 16,711,184Transaction costs(309.000)Exercise of warrants3,608,571Net cash from financing activities3,198,869Effect of foreign exchange on cash- 22,680Change in cash for the year(734,048)Cash, beginning of year1,913,7421,619,742		(100,702)	(78,731)
Convertible debt issued, net of repayments- (4,000,000)Proceeds on share issuance, net of share issuance costs- 16,711,184Transaction costs(309.000)Exercise of warrants3,608,5712,575,200Net cash from financing activities3,198,86915,180,494Effect of foreign exchange on cash- 22,680Change in cash for the year(734,048)7,601,307Cash, beginning of year1,913,7421,619,742		-	,
Proceeds on share issuance, net of share issuance costs - 16,711,184   Transaction costs (309.000)   Exercise of warrants 3,608,571 2,575,200   Net cash from financing activities 3,198,869 15,180,494   Effect of foreign exchange on cash - 22,680   Change in cash for the year (734,048) 7,601,307   Cash, beginning of year 1,913,742 1,619,742		-	
Transaction costs (309.000) -   Exercise of warrants 3,608,571 2,575,200   Net cash from financing activities 3,198,869 15,180,494   Effect of foreign exchange on cash - 22,680   Change in cash for the year (734,048) 7,601,307   Cash, beginning of year 1,913,742 1,619,742			
Exercise of warrants 3,608,571 2,575,200   Net cash from financing activities 3,198,869 15,180,494   Effect of foreign exchange on cash - 22,680   Change in cash for the year (734,048) 7,601,307   Cash, beginning of year 1,913,742 1,619,742			-
Net cash from financing activities   3,198,869   15,180,494     Effect of foreign exchange on cash   -   22,680     Change in cash for the year   (734,048)   7,601,307     Cash, beginning of year   1,913,742   1,619,742	Exercise of warrants		2,575,200
Effect of foreign exchange on cash-22,680Change in cash for the year(734,048)7,601,307Cash, beginning of year1,913,7421,619,742	Net cash from financing activities		
Change in cash for the year (734,048) 7,601,307   Cash, beginning of year 1,913,742 1,619,742		0,170,007	10,100,171
Cash, beginning of year   1,913,742   1,619,742	Effect of foreign exchange on cash	-	22,680
	Change in cash for the year	(734,048)	7,601,307
Cash, end of year \$ 1,179.694 \$ 9.221.049	Cash, beginning of year	1,913,742	1,619,742

## 1. NATURE OF OPERATIONS AND GOING CONCERN

Siyata Mobile Inc. ("Siyata" or the "Company") was incorporated under the Business Corporations Act, British Columbia on October 15, 1986. The Company's shares are listed on NASDAQ under the symbol SYTA and warrants issued on September 29, 2020, are traded under the symbol SYTAW. The Company's principal activity is the sale of vehicle-mounted, cellular-based communications platforms over advanced mobile networks and cellular booster systems. The registered and records office is located at 2200 - 885 West Georgia Street, Vancouver, BC V6C 3E8.

These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") IAS 34 *Interim Financial Reporting*, with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than a process of forced liquidation. These unaudited condensed interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company incurred a net loss of \$7,583,252 during the three month period ended March 31, 2023 (March 31, 2022- three month period net loss of \$3,879,909), and, as of that date, the Company's total deficit was \$85,401,915 (December 31, 2022 - \$77,818,663). The Company's continuation as a going concern is dependent upon the success of the Company's sale of inventory, the existing cash flows, and the ability of the Company to obtain additional debt or equity financing, all of which are uncertain. These material uncertainties raise substantial doubt on the Company's ability to continue as a going concern.

## 2. BASIS OF PREPARATION

#### Statement of compliance

These unaudited condensed interim consolidated financial statements, including comparatives, have been prepared in accordance with International Accounting Standards (IAS) 34 *Interim Financial Reporting*. Omitted from these financial statements are certain information and note disclosures normally included in the annual financial statements. These financial statements and notes presented should be read in conjunction with the annual financial statements for the year ended December 31, 2022.

The accounting methods and principles of computation adopted in these financial statements are the same as those in annual consolidated financial statements for the year ended December 31, 2022.

The preparation of these unaudited condensed interim consolidated financial statements requires management to make estimates, judgments and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The significant judgements made by management when applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the Company's December 31, 2022 annual consolidated financial statements.

## 2. BASIS OF PREPARATION (cont'd)

#### **Basis of consolidation and presentation**

These unaudited condensed interim consolidated financial statements of the Company have been prepared on a historical cost basis, except for financial instruments classified as financial instruments at fair value through profit and loss, which are stated at their fair value. In addition, the condensed interim consolidated financial statements have been prepared using the accrual basis of accounting, except for the statement of cash flows.

These unaudited condensed interim consolidated financial statements incorporate the financial statements of the Company and its wholly controlled subsidiaries. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities. These condensed interim consolidated financial statements include the accounts of the Company and its direct wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated.

The unaudited condensed interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries:

Name of Subsidiary	Place of Incorporation	Ownership
Queensgate Resources Corp.	British Columbia, Canada	100%
Queensgate Resources US Corp.	Nevada, USA	100%
Siyata Mobile (Canada) Inc.	British Columbia, Canada	100%
Siyata Mobile Israel Ltd.	Israel	100%
Signifi Mobile Inc.	Quebec, Canada	100%
ClearRF Nevada Ltd.	Nevada, USA	100%

#### **Recent adoptions of accounting pronouncements**

The following amendments became effective on January 1, 2023, and did not have a material impact on the Company's condensed interim consolidated financial statements:

- In February 2021, the IASB issued Definition of Accounting Estimates (Amendments to IAS 8). The amendments define accounting estimates and clarify the distinction between changes in accounting estimates and changes in accounting policies.
- In February 2021, the IASB issued Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2). The amendments provide guidance to help entities disclose their material (previously "significant") accounting policies.
- In May 2021, the IASB issued Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12). The amendments narrow the scope of the recognition exemption so that companies would be required to recognize deferred tax for transactions that give rise to equal amounts of taxable and deductible temporary differences, such as leases.

## 2. BASIS OF PREPARATION (cont'd)

#### Future accounting pronouncements

The standards, amendments, and interpretations issued before 2023 but not yet adopted by the Company have been disclosed in Note 3 of the Company's December 31, 2022 annual consolidated financial statements. The Company is currently considering the impact of adopting these standards, amendments and interpretations on its consolidated financial statement.

# 3. TRADE AND OTHER RECEIVABLES

	March 31, D	ecember 31,
	2023	2022
Trade receivables	\$ 1,645,627 \$	2,015,291
Allowance for doubtful accounts	(1,062,052)	(1,056,393)
Taxes receivable	527,548	615,730
Total	\$ 1,111,123 \$	1,574,628

## 4. INVENTORY

	March 31, Do	ecember 31,
	2023	2022
Finished products	\$ 6,874,848 \$	7,392,002
Impairment of finished products	(3,555,683)	(3,555,683)
Accessories and spare parts	663,645	675,001
Impairment of accessories and spare parts	(418,770)	(418,770)
Total	\$ 3,564,040 \$	4,092,550

## 5. CONVERTIBLE DEBENTURES

On November 3, 2021, the Company issued a US\$7,200,000 convertible promissory note (the "Promissory Note") and 2,142,857 warrants for gross proceeds of US\$6,000,000. The Company elected to measure the promissory note (hybrid contract) at fair value through profit or loss ("FVTPL") on initial recognition and, as such, the embedded conversion feature was not separated. The warrants were recorded as a liability.

During the three months ended March 31, 2022, the Company completed a secondary offering of its common shares, and as a result of the terms of the convertible promissory note, the Company was required to direct 20% of the gross proceed of the offering to the lender. A total of US\$4,000,000 was repaid to the lender on January 13, 2022. Commencing in May 2022, the Company made monthly payments of \$400,000 through issuance of common shares towards the principal balance of the promissory note, resulting the promissory note being fully repaid by December 31, 2022. The Company issued 13,112,255 common shares, with a total market value of \$4,138,002. The difference between the fair value of the shares issued, and the value of the principal repaid of \$938,002 was included in profit and loss in the change in fair value of convertible promissory note.

For the three months ended March 31, 2022 the Company recorded a fair value loss of \$2,023,751 on the Convertible debenture.

#### Siyata Mobile Inc.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements (Expressed in US dollars) As at March 31, 2023 and December 31, 2022 and for the three months ended March 31, 2023 and 2022

#### 6. WARRANT LIABILITY

The balance of the warrant liability is as follows:

		November 3, 2021		January 11, 2022	October 12, 2022		January 19, 2023		Total
Balance December 31, 2022	<b>\$</b> 1	97,733	\$	501,330	\$ 2	2,035,741	\$	- :	\$ 2,734,804
Exercise of warrants	(23	84,554)		-	(2	2,420,699)		-	(2,705,253)
Warrants issued		-		-		-	2,875,58	0	2,875,580
Transfer to equity		-		-		(564,946)	(3,410,10	0)	(3,975,046)
Change in fair value	:	86,821		127,435		949,904	534,52	0	1,698,680
Balance March 31, 2023	\$	-	\$	628,765	\$	-	\$	- :	\$ 628,765

## January 19, 2023 warrants

On January 19, 2023, the Company entered into warrant exercise agreements with fourteen existing accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 18,042,857 of the Company's common shares. In consideration for the immediate exercise of the outstanding warrants for cash, the Company agreed to reduce the exercise price from \$0.23 to \$0.20 per share and issue new unregistered warrants to purchase up to an aggregate of 18,042,857 common shares with an exercise price of \$0.20 per share. The gross proceeds to the Company from the exercise totaled approximately \$3,608,571, prior to deducting warrant inducement agent fees and offering expenses.

The new warrants are exercisable immediately upon issuance at an exercise price of \$0.20 per share and have a term of exercise equal to five years. In connection with the exercise, the Company will be required pursuant to the terms of 2,989,130 of its remaining unexercised common share purchase warrants, to reduce the exercise price of such warrants from \$0.23 per common share to an exercise price of \$0.20 per common share.

On March 30, 2023, the SEC accepted the registration statement of the Company to the effect that all of the 21,031,987 outstanding \$0.20 warrants become immediately a cashless exercise and their underlying shares become immediately tradeable. Subsequent to the quarter ended March 31, 2023, 17,116,987 warrants were exercised cashless in exchange for 17,116,987 common shares of the Company with 3,915,000 cashless warrants remaining unexercised. All of the warrants that became cashless exercise were transferred to equity at March 30, 2023, as they no longer met the definition of a liability.

The fair value of the warrants issued at January 19, 2023 was \$2,875,580 and was determined using the stock price at the date of issue, with a 15% discount for lack of marketability. This method was used as the warrants contained an alternative cashless exercise feature.

The fair value of the warrants on March 30, 2023 was \$3,410,100 and was determined using the stock price on the date, as the warrants were cashless exercise at that date.

## 6. WARRANT LIABILITY (Cont'd)

#### November 3, 2021 warrants

The warrants allowed for the purchase of 1,892,857 common shares of the Company at an exercise price of US 4.00 per common share and expired 5 years from the issue date of the related promissory note. Under the terms of the warrants, the exercise price of the warrant was adjusted to \$2.30 when an offering was closed on January 3, 2022 that issued shares at a price lower than the exercise price. On January 19, 2023 the warrant holders entered into the agreement noted above to exercise the warrants, and receive new warrants in exchange.

At December 31, 2022 the fair value of the warrants was \$197,733 and was determined using a Black-Scholes option pricing model with the following assumptions: initial stock price \$0.15, strike rate \$0.23 dividend yield 0%, term 3.84 years, volatility 110% and risk-free rate 4.08%.

At January 19, 2023 prior to exercise, the fair value of the warrants was \$284,554 and was determined using a Black-Scholes option pricing model with the following assumptions: initial stock price \$0.19, strike rate \$0.20 dividend yield 0%, term 3.79 years, volatility 130% and risk-free rate 3.62%.

#### January 11, 2022 warrants

The Company assessed that the 8,519,999 warrants, and 1,480,000 pre-funded warrants issued in the January 2022 equity offering did not meet the "fixed for fixed" test and are therefore recorded as liabilities at fair value through profit and loss, and revalued at the end of each period.

At December 31, 2022 the fair value of the warrants was \$501,330 and was determined using a Black-Scholes option pricing model with the following assumptions: initial stock price \$0.15, strike rate \$2.30, dividend yield 0%, term 4.03 years, volatility 110% and risk-free rate 4.08%.

At March 31, 2023 the fair value of the warrants was \$628,765 and was determined using a Black-Scholes option pricing model with the following assumptions: initial stock price \$0.19, strike rate \$2.30, dividend yield 0%, term 3.79 years, volatility 125% and risk-free rate 3.69%.

#### October 12, 2022 warrants

The Company assessed that the 17,400,000 warrants and 1,590,000 pre-funded warrants issued as part of the October 2022 equity offering did not meet the "fixed for fixed" test and are therefore reported as liabilities at fair value through profit and loss, and revalued at the end of each period. On January 19, 2023 the warrant holders entered into the agreement noted above to exercise 16,150,000 of the 17,400,000 warrants, and receive new warrants in exchange. The remaining 1,250,000 warrants that were outstanding at January 19, 2023 were converted to cashless exercise warrants on March 30, 2023 as described above.

#### 6. WARRANT LIABILITY (Cont'd)

The fair value of the warrants as at December 31, 2022 was \$1,850,758 and was determined using the Black-Scholes Option Pricing Model with the following assumptions: share price: \$0.15; exercise price \$0.23; expected volatility: 100%; dividend yield 0%; risk free rate: 3.98%.

The fair value of the warrants on January 19, 2023 was \$2,608,059 and was determined using the Black-Scholes Option Pricing Model with the following assumptions: share price: \$0.19; exercise price \$0.20; term 4.73 years; expected volatility: 115%; dividend yield 0%; risk free rate: 3.49%.

The fair value of the outstanding warrants on March 30, 2023 prior to the transfer to equity was \$564,946 and was determined using the stock price on the date, as the warrants were cashless exercise at that date.

In connection with the October 2022 equity offering, the Company issued 1,739,130 waiver warrants exercisable at \$0.23 per share which expire, if unexercised, on October 12, 2027, to entice the holder of the convertible promissory note to waive their right to block the equity offering. The waiver warrants did not meet the "fixed for fixed" test and are therefore reported as liabilities at fair value through profit and loss and revalued at the end of each period. On March 30, 2023, the waiver warrants were modified to cashless exercise as described above, and therefore met the "fixed for fixed" test and were reclassified to equity.

The fair value of the waiver warrants as at December 31, 2022 was \$184,983 and was determined using the Black-Scholes Option Pricing Model with the following assumptions: share price: \$0.15; exercise price \$0.23; expected volatility: 100%; dividend yield 0%; risk free rate: 3.10%.

The fair value of the waiver warrants as at March 30, 2023 prior to transfer to equity was \$328,696 and was determined using the stock price on the date, as the warrants were cashless exercise at that date.

# 7. SHARE CAPITAL

(a) Authorized Unlimited number of common shares without par value

As at March 31, 2023, the Company had 62,911,417 common shares issued and outstanding (December 31, 2022 – 44,868,560).

As of the date of issuance of these financial statements total outstanding common shares is 80,028,404.

#### (b) Common share transactions

Transactions for the three months ended March 31, 2023 are as follows:

• The Company issued 18,042,857 common shares on the exercise of various warrants for gross proceeds of \$3,608,571. Additionally, the Company issued 18,042,857 warrants to replace those warrants that were exercised. As an incentive to investors to exercise the 18,042,857 warrants, the Company issued cashless warrants to those investors that were exercisable as of March 30, 2023. As well, any holders of the \$0.23 warrants that had a ratchet provision also became cashless. As a result, 17,116,987 common shares were issued for cashless warrants subsequent to March 31, 2023 as described in Note 16.

#### Transactions for the three months ended March 31, 2022 are as follows:

• On January 11, 2022, the Company completed an underwritten public offering in the United States, raising a total of \$20,013,043 in gross proceeds. The Company allocated the gross proceeds firstly to the warrant liabilities, with the remainder to the common shares. Direct costs have been allocated based on the percentage allocation of the proceeds. The underwritten public offering resulted in the sale to the public of 7,215,652 Units at \$2.30 per Unit, with each Unit being comprised of one common share and one warrant (the "Unit Warrants") exercisable at \$2.30 per share. The Unit warrants are exercisable immediately and have a term of 5 years. Gross proceeds of \$10,936,974 were allocated to the common shares, and \$5,395,878 to the unit warrants liability.

In addition, the Company issued 1,480,000 pre-funded units ("Pre-Funded Units") at \$2.29 per Pre-Funded Unit. Each Pre-Funded Unit is comprised of a one-pre-funded warrant (a "Pre-Funded Warrant") to purchase one common share, and one warrant to purchase one common share. The Pre-Funded Warrant allows the holder to acquire one common share of the Company at an exercise price of \$0.01 per common share, and a warrant to purchase a common share at an exercise price of \$2.30 per share. The warrants are exercisable immediately and have a term of 5 years. Each Pre-Funded Warrant is exercisable immediately and is exercisable until all Pre-Funded Warrants are exercised. Proceeds of \$2,560,400 were allocated to the pre-funded warrants and \$1,106,747 to the unit warrants in the warrant liability.

The Company determined that the pre-funded warrants within the Pre-funded Units are common shares in substance, as they require only a minimal exercise price of \$0.01. In addition, the underwriting agreement includes both the Units and Pe-funded Units and were negotiated together in the equity raise. Given that the purpose of the Prefunded Unit is in substance the same as that of the Unit (i.e., resulting in the ownership of both common shares and common share warrants) and that the terms of the warrants in both the Units and Prefunded Units are the same (i.e., the obligations of the Company for the units are the same), the Company determined that the Units and Pre-funded Units are closely related and should be combined into one unit of account for the purposes of allocating proceeds.

#### 7. SHARE CAPITAL (cont'd)

#### b) Common share transactions (cont'd)

Therefore, the proceeds from the sale of the Units and Pre-funded Units are combined and allocated among the common shares, pre-funded warrants, and the common share warrants using the residual method, with the warrant liability being initially recognized at fair value as of the registration date and the residual amount being allocated to the common shares (i.e., equity).

The Company concurrently sold an additional 1,304,347 warrants to purchase 1,304,347 common shares exercisable at \$2.30 per share (the "Option Warrants") pursuant to an over-allotment option exercised by the underwriter. The exercise price of the warrants issued in connection with the exercise of the over-allotment option was \$0.0097 per warrant. Each Option Warrant is exercisable immediately and has a term of five years from the issue date. Proceeds of \$975,393 were allocated to the option warrant liability. As the fair value of the warrant liability exceeded the proceeds received on the warrants of \$13,043, a fair value loss of \$962,350 was recognized in the statement of profit and loss as a fair value change in the opening warrant liability.

The fair value of the common shares and pre-funded units was determined by reference to the market price on the day of the offering, which was \$1.73 per share. The Unit Warrants, Warrants, and Option Warrants were valued using the Black-Scholes model using the following assumptions: initial stock price \$1.73, strike rate \$2.30, dividend yield 0%, term 5 years, volatility 60.0% and risk-free rate 0.50%.

The Company also issued warrants to the placement agents to purchase 434,783 common shares at an exercise price of \$2.53 per share (the "Placement Agent Warrants"), which are exercisable 180 days from January 11, 2022, with a term of five years. The fair value of the Placement Agent Warrants was determined to be \$307,189 using the Black-Scholes model with the following assumptions: initial stock price \$1.73, strike rate \$2.53, dividend yield 0%, term 5 years, volatility 60.0% and risk-free rate 0.50%.

The Company assessed that the warrants issued under the public offering, excluding the Placement Agent Warrants did not meet the "fixed for fixed" test and are therefore reported as liabilities at fair value through profit and loss, and revalued at the end of each period. The Placement Agent Warrants were assessed under IFRS 2 *Share Based Payments*, as equity-settled share-based payments and have been recorded in equity.

The direct costs related to the issuance of the common shares and warrants issued in the January 2022 underwritten public offering were \$2,016,895, including the value of the Placement Agent Warrants. Direct costs of \$965,248 were allocated to the warrant liability and expensed immediately in profit and loss. During the period, 1,480,000 Pre-Funded Warrants were exercised for gross proceeds of \$14,800, converting into 1,480,000 common shares that were fully issued.

## 7. SHARE CAPITAL (cont'd)

## (b) Common share transactions (cont'd)

• On March 31, 2022, as part of the ClearRF acquisition (Note 3), the Company issued 138,958 shares to the vendor with a fair value of \$190,094.

## (c) Stock options

The Company has a shareholder-approved "rolling" stock option plan (the "Plan") in compliance with Nasdaq policies. Under the Plan the maximum number of shares reserved for issuance may not exceed 15% of the total number of issued and outstanding common shares at the time of granting. The exercise price of each stock option shall not be less than the market price of the Company's stock at the date of grant, less a discount of up to 25%. Options can have a maximum term of ten years and typically terminate 90 days following the termination of the optionee's employment or engagement, except in the case of retirement or death. Vesting of options is at the discretion of the Board of Directors at the time the options are granted.

A summary of the Company's stock option activity is as follows:

	Number of stock options	Av Ex	eighted verage kercise Price
Outstanding options, December 31, 2021	414,568	\$	13.88
Granted	1,145,000	\$	1.15
Expired/Cancelled	(53,430)	\$	30.90
Outstanding options, December 31, 2022 and March 31, 2023	1,506,138	\$	3.53

# (c) Stock options (cont'd)

As at March 31, 2023 stock options outstanding are as follows:

Grant Date	Number of options outstanding	Number of options exercisable	Weighted Average Exercise Price Expiry date			Remaining contractual life (years)
24-Dec-18	12,896	12,896	\$	54.00	24-Dec-23	0.63
15-Jan-19	828	828	\$	54.00	15-Jan-24	0.69
21-Mar-19	12,345	12,345	\$	59.00	21-Mar-24	0.87
01-Jan-20	2,069	2,069	\$	54.00	01-Jan-24	0.65
15-Nov-20	95,000	95,000	\$	6.00	15-Nov-30	7.53
15-Nov-20	161,500	161,500	\$	6.00	15-Nov-25	2.52
02-Jan-21	57,000	57,000	\$	11.50	02-Jan-26	2.65
02-Jan-21	5,000	5,000	\$	11.50	02-Jan-31	7.66
18-Jan-21	14,500	14,500	\$	11.50	18-Jan-26	2.70
01-Jan-22	20,000	12,500	\$	4.00	29-Oct-26	3.48
13-Apr-22	795,000	265,000	\$	1.10	13-Apr-27	3.93
12-Jul-22	330,000	110,000	\$	1.10	12-Jul-25	2.18
Total	1,506,138	748,638	\$	3.53		3.51

Transactions for the three months ended March 31, 2022 are as follows:

• On January 1, 2022, the Company granted 20,000 stock options at \$4.00 per share that vest in 8 equal quarterly periods with the first vesting occurring on the grant date. The fair value on the date of the grant was \$54,480 (\$2.724 per option).

## (d) Restricted share units

The Company approved on February 14, 2022, the addition of the issuance of restricted share units to the existing executive stock option plan.

A summary of the Company's restricted share unit activity is as follows:

	Number of RSU's	Av I	eighted verage Issue Price
Outstanding RSU, December 31, 2021	-	\$	-
Granted	3,195,000	\$	1.05
Exercised	(30,000)	\$	1.10
Outstanding RSU, December 31, 2022 and March 31, 2023	3,165,000	\$	1.05

As at March 31, 2023 restricted share units outstanding are as follows:

	Number of RSU's			ighted erage
Grant Date	outstanding	exercisable	Issu	e Price
09-Mar-22	2,250,000	1,200,000	\$	1.03
13-Apr-22	825,000	513,750	\$	1.10
12-Jul-22	90,000	37,500	\$	1.10
Outstanding RSU, March 31, 2023	3,165,000	1,751,250	\$	1.05

Transactions for the three months ended March 31, 2022, are as follows:

- On March 9, 2022, the Company granted 450,000 RSU's to Directors that vest immediately. On the date of granting, the fair value and stock price was \$1.03/share.
- On March 9, 2022, the Company granted 1,800,000 RSU's to a Director that vest quarterly over 12 periods with the first vesting of 150,000 RSU's occurring on the date of the granted and another 150,000 vest every three months until all of the granted RSU's have vested. On the date of granting, the fair value and the stock price was \$1.03/share.

## (e) Agents' options

A summary of the Company's agent options activity is as follows:

	Number of	Weighted average	
	options	exercis	se price
Outstanding agent options, December 31, 2021	445,926	\$	7.51
Granted	487,283	\$	2.51
Expired	(1,702)	\$	20.49
Outstanding agent options, December 31, 2022 and March 31, 2023	931,507	\$	4.12

As at March 31, 2023 agent options outstanding are as follows:

Grant Date	Number of options outstanding	Number of options exercisable	Av Ex	eighted verage vercise Price	Expiry date	Remaining contractual life (years)
29-Sep-20	113,500	113,500	\$	6.60	28-Sep-25	2.00
29-Sep-20	266,000	266,000	\$	6.85	28-Sep-25	2.00
31-Dec-20	64,724	64,724	\$	11.50	30-Jun-24	1.00
11-Jan-22	434,783	434,783	\$	2.53	11-Jan-27	4.00
01-Apr-22	52,500	52,500	\$	2.30	08-Mar-27	4.00
Total	931,507	931,507	\$	4.12		2.98

Transactions for the three months ended March 31, 2022 are as follows:

• The Company issued warrants to the placement agents to purchase 434,783 common shares at an exercise price of \$2.53 per share (the "Placement Agent Warrants"), which are exercisable 180 days from January 11, 2022, with a term of five years. The fair value of the Placement Agent Warrants was determined to be \$307,189 using the Black-Scholes model with the following assumptions: initial stock price \$1.73, strike rate \$2.53, dividend yield 0%, term 5 years, volatility 60.0% and risk-free rate 0.50%. The Company also issued 52,500 agent's options with a fair value of \$61,950 with an exercise price of \$2.30.

#### (f) Share purchase warrants

A summary of the Company's share purchase warrant activity is as follows:

	Number of Warrants	Weighted average exercise price		
Outstanding, December 31, 2021	5,121,328	\$	7.64	
Granted	29,139,129	\$	0.94	
Expired	(128,386)	\$	33.47	
Outstanding, December 31, 2022	34,132,071	\$	1.76	
Granted	18,042,857		0.20	
Exercised	(18,042,857)		0.20	
Outstanding, March 31, 2023	34,132,071	\$	1.47	

As at March 31, 2023 the share purchase warrants outstanding are as follows:

	Number of Warrants outstanding and	]	Exercise	
Grant Date	exercisable		Price	Expiry date
29-Sep-20	1,805,585	\$	6.85	28-Sep-25
31-Dec-20	1,294,500	\$	11.50	30-Jun-24
11-Jan-22	9,999,999	\$	2.30	11-Jan-27
12-Oct-22	1,250,000		Cashless	11-Jan-27
12-Oct-22	1,739,130		Cashless	11-Jan-27
19-Jan-23	18,042,857		Cashless	18-Jan-28
Total	34,132,071	\$	1.47	

Transactions for the three months ended March 31, 2023 are as follows:

• 18,042,857 warrants were exercised. The Company issued 18,042,857 warrants to replace those warrants that were exercised. As an incentive to investors to exercise the 18,042,857 warrants, the Company issued cashless warrants to those investors that were exercisable as of March 31, 2023. As well, any holders of the \$0.23 warrants that had a ratchet provision also became cashless. As a result, 17,116,987 cashless warrants were exercised subsequent to March 31, 2023.

Transactions for the three months ended March 31, 2022 are as follows:

- 128,386 share purchase warrant expired in 2022.
- On January 11, 2022 as part of an underwritten public offering, the Company issued a total of 9,999,999 share purchase warrants, exercisable at \$2.30 per warrant and with a term of five years.

# Siyata Mobile Inc.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements (Expressed in US dollars) As at March 31, 2023 and December 31, 2022 and for the three months ended March 31, 2023 and 2022

# 8. COST OF SALES

(in thousands)	March 31, 2023	N	March 31, 2022	
Inventory expensed	\$ 971	\$	359	
Royalties	106	j	54	
Other expenses	229	)	165	
Total	\$ 1,306	\$	578	

# 9. SELLING AND MARKETING EXPENSES

(in thousands)	March 31, 2023	March 31, 2022
Salaries and related expenses	\$ 705	\$ 618
Advertising and marketing	249	398
Travel and conferences	49	29
Total	\$ 1,003	\$ 1,045

# 10. GENERAL AND ADMINISTRATIVE EXPENSES

(in thousands)	March 31, 2023	March 31, 2022	
Salaries and related expenses	\$ 151	\$ 125	
Professional services	565	377	
Consulting and director fees	263	419	
Travel	14	36	
Office and general	326	442	
Regulatory and filing fees	27	21	
Shareholder relations	46	239	
Total	<u>\$ 1,392</u>	\$ 1,659	

#### **11. TRANSACTION COSTS**

Transaction costs incurred in relation to the January 2023 warrant raise and issuance described in Note 7 were \$309,000 and were included in the change in fair value of warrant liability on the statement of operations.

Transaction costs incurred in the three months ended March 31, 2022 were \$965,247, which are costs incurred for the January 11, 2022 capital raise that were allocated to the warrant liability and expensed through the statement of operations.

## **12. FINANCIAL INSTRUMENTS**

The fair values of the Company's cash, trade and other receivables, accounts payable and accrued liabilities and long-term debt, approximate carrying value, which is the amount recorded on the consolidated statement of financial position.

#### Credit risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company places its cash with institutions of high creditworthiness. Management has assessed there to be a low level of credit risk associated with its cash balances.

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the demographics of the Company's customer base, including the default risk of the industry and country in which customers operate, as these factors may have an influence on credit risk. Approximately 34% of the Company's revenue for the three months ended March 31, 2023 (March 31, 2022 - 23%) is attributable to sales transactions with a single customer.

The Company has established a credit policy under which each new customer is analyzed individually for creditworthiness before the Company's standard payment and delivery terms and conditions are offered. The Company's review includes external ratings, when available, and in some cases bank references. Purchase limits are established for each customer, which represents the maximum open amount without requiring approval from the Risk Management Committee; these limits are reviewed quarterly. In prior years, certain key customers were offered extended payment terms on their purchases due to slow down from Covid-19 and budget approvals for government tenders.

As a result, the Company had customers with overdue receivables on their books which resulted in the Company taking a bad debt provision on these overdue receivables which amounted to \$1,062,052 at March 31, 2023 (March 31, 2022 - \$1,056,393).

## 12. FINANCIAL INSTRUMENTS (Cont'd)

More than 50% (2022 - 18%) of the Company's customers have been active with the Company for over four years, and the allowance for doubtful accounts of \$1,062,052 (2022 - \$1,056,393) has been recognized against these customers. In monitoring customer credit risk, customers are grouped according to their credit characteristics, including whether they are an individual or legal entity, whether they are a wholesale, retail or end-user customer, geographic location, industry, aging profile, maturity, and the existence of previous financial difficulties. Trade and other receivables relate mainly to the Company's wholesale customers. Customers that are graded as "high risk" are placed on a restricted customer list and monitored by the Company.

The carrying amount of financial assets represents the maximum credit exposure, notwithstanding the carrying amount of security or any other credit enhancements.

## Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company examines current forecasts of its liquidity requirements so as to make certain that there is sufficient cash for its operating needs, and it is careful at all times to have enough unused credit facilities so that the Company does not exceed its credit limits and is in compliance with its financial covenants (if any). These forecasts take into consideration matters such as the Company's plan to use debt for financing its activity, compliance with required financial covenants, compliance with certain liquidity ratios, and compliance with external requirements such as laws or regulation.

The Company uses activity-based costing to cost its products and services, which assists it in monitoring cash flow requirements and optimizing its cash return on investments. Typically, the Company ensures that it has sufficient cash on demand to meet expected operational expenses for a period of 90 days, including the servicing of financial obligations; this excludes the potential impact of extreme circumstances that cannot reasonably be predicted, such as natural disasters.

With the exception of employee benefits, the Company's accounts payable and accrued liabilities have contractual terms of 90 days. The employment benefits included in accrued liabilities have variable maturities within the coming year.

# 12. FINANCIAL INSTRUMENTS (Cont'd)

#### Market risk

a) Currency Risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

b) Interest Rate Risk

Interest rate risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in interest rates. The Company's sensitivity to interest rates is inherently involved in the calculation of the fair value of the warranty liability which are revalued based on changes parameters which include the prevailing interest rate.

c) Price Risk

The Company is exposed to price risk with respect to equity prices. Equity price risk is defined as the potential adverse impact on the Company's earnings due to movements in individual equity prices or general movements in the level of the stock market. The Company closely monitors individual equity movements, and the stock market to determine the appropriate course of action to be taken by the Company.

#### **13. RELATED PARTY TRANSACTIONS**

#### Key Personnel Compensation

Key management personnel includes those persons having authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The Company has determined that key management personnel consists of executive and non-executive members of the Company's Board of Directors and corporate officers. The remuneration of directors and key management personnel for the three months ended March 31, 2023 and 2022 are as follows:

	 2023		2022
Payments to key management personnel:			
Salaries, consulting and directors' fees	\$ 285,413	\$	491,889
Share-based payments	 243,323		767,436
Total	\$ 528,736	\$ 1	1,259,325

# 13. RELATED PARTY TRANSACTIONS (cont'd)

Salaries, consulting and directors' fees shown above are classified within profit and loss as shown below:

			(in tho	isands)		
Type of Service	Nature of Relationship	2	023	2	2022	
Selling and marketing expenses	VP Technology/VP Sales International	\$	46	\$	84	
General and administrative expense	Companies controlled by the CEO, CFO and Directors	\$	239	\$	408	

# **14. SEGMENTED INFORMATION**

The Company is domiciled in Canada, and it operates and produces its income primarily in Israel, Europe and North America. The Company operates as a single segment being the sale of cellular-based communications products.

The Company's entity-wide disclosures include disaggregated information about product sales, geographical areas, and major customers.

Geographical area information is shown below:

# External revenues by Geography for the three months ended March 31

(in thousands)	2023	 2022	
USA	\$ 1,073	\$ 245	
Canada	219	249	
EMEA	511	326	
Australia	-	13	
Total	\$ 1,803	\$ 833	

## 14. SEGMENTED INFORMATION (cont'd)

Non-current asset geographic area information is shown below:

(in thousands)	March 31, 2023	December 31, 2022		
Long-term receivable total	<u>\$ 146</u>	\$ 150		
Canada	-	-		
EMEA	146	150		
Right of use asset total	\$ 812	\$ 887		
Canada	118	177		
EMEA	694	710		
Equipment total	\$ 200	\$ 207		
Canada	-	-		
EMEA	200	207		
Intangibles total	<u>\$ 7,481</u>	\$ 6,988		
Canada				
EMEA	7,481	6,988		

Product information is shown below:

## Revenue by product line for the three months ended March 31

(in thousands)	2023		2022	
Cellular boosters and related accessories	\$ 438	\$	463	
Rugged devices and related accessories	 1,365		370	
Total	\$ 1,803	\$	833	

# 15. SUPPLEMENTAL INFORMATION WITH RESPECT TO CASH FLOWS

	Three months ended March 31
	2023 2022
Change in non-cash working capital:	
Trade and other receivables	<b>\$ 463,505 \$</b> (6,303)
Prepaids	<b>(491,942)</b> (731,566)
Inventory	<b>528,510</b> (1,060,581)
Advances to suppliers	<b>(519,709)</b> (590,506)
Accounts payable and accrued liabilities	<b>(967,476)</b> (836,698)
Deferred revenue	(149,600)
	<b>\$(1,136,712) \$</b> (3,225,654)

During the three months ended March 31, 2023, the Company paid \$nil (March 31, 2022 - \$2,659) in interest and \$Nil (March 31, 2022 - \$nil) in income taxes.

# **16. SUBSEQUENT EVENTS**

Subsequent to the period end, a total of 17,116,987 cashless warrants were exercised in exchange for common shares of the Company.

The Company was issued a cease trading order by the British Columbia Securities Exchange for late filing of these Q1 2023 financial statements that were due on May 15, 2023.

The Company entered into a factoring agreement for their receivables.